Open Payments

KFH - ANTIOCH

Type
Teaching hospital
Where
Antioch, CA
Medicare CCN
050760
Received
$6,618,480 in 284 records, 2022 ($0 general, $6,618,480 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022Research payment284$6,618,480

By company

CompanyRecordsAmountYears
PFIZER INC.284$6,618,4802022

By nature of payment

NatureRecordsAmount
Research payment284$6,618,480

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-21PFIZER INC.$3,900Research paymentCash or cash equivalentA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2022
2022-12-21PFIZER INC.$1,046Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-12-20PFIZER INC.$3,831Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2022
2022-12-20PFIZER INC.$1,620Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-12-16PFIZER INC.$31,497Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-12-16PFIZER INC.$13,500Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-12-16PFIZER INC.$3,240Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-12-15PFIZER INC.$17,820Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-12-15PFIZER INC.$1,579Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-12-14PFIZER INC.$430,366Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-12-14PFIZER INC.$31,086Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-12-14PFIZER INC.$1,514Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-12-14PFIZER INC.$378Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-12-13PFIZER INC.$10,216Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2022
2022-12-09PFIZER INC.$28,180Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-12-08PFIZER INC.$8,579Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-12-07PFIZER INC.$3,150Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-12-07PFIZER INC.$1,135Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-12-07PFIZER INC.$757Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-12-06PFIZER INC.$10,216Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2022
2022-12-02PFIZER INC.$3,240Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-11-29PFIZER INC.$3,831Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2022
2022-11-23PFIZER INC.$6,151Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-11-16PFIZER INC.$25,953Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-11-16PFIZER INC.$8,000Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-11-15PFIZER INC.$69,288Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-11-15PFIZER INC.$12,454Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-11-15PFIZER INC.$8,791Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-11-15PFIZER INC.$4,087Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-11-15PFIZER INC.$1,277Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2022
2022-11-09PFIZER INC.$12,500Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-11-08PFIZER INC.$4,046Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2022
2022-11-04PFIZER INC.$8,939Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2022
2022-10-28PFIZER INC.$25,278Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2022
2022-10-26PFIZER INC.$44,321Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-10-26PFIZER INC.$10,428Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST2022
2022-10-26PFIZER INC.$2,085Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-10-26PFIZER INC.$48Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-10-25PFIZER INC.$24,302Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-10-18PFIZER INC.$132,041Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2022
2022-10-06PFIZER INC.$6,275Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-10-06PFIZER INC.$1,400Research paymentCash or cash equivalentA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2022
2022-10-05PFIZER INC.$45,940Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-10-01PFIZER INC.$6,271Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-10-01PFIZER INC.$5,211Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-10-01PFIZER INC.$1,589Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-10-01PFIZER INC.$1,311Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-09-29PFIZER INC.$2,073Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-09-28PFIZER INC.$7,890Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-09-27PFIZER INC.$8,300Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-09-23PFIZER INC.$101,390Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-09-22PFIZER INC.$192,312Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-09-22PFIZER INC.$140,566Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-09-21PFIZER INC.$115,660Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-09-21PFIZER INC.$2,627Research paymentCash or cash equivalentA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2022
2022-09-12PFIZER INC.$642,623Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYCLINICAL CHARACTERISTICS TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH HRHER2 BREAST CANCER IN THE UNITED STATES2022
2022-08-24PFIZER INC.$44,050Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-24PFIZER INC.$37,000Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-08-24PFIZER INC.$35,000Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-08-24PFIZER INC.$897Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2022
2022-08-23PFIZER INC.$2,045Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-08-20PFIZER INC.$4,239Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-08-17PFIZER INC.$36,800Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-08-17PFIZER INC.$7,181Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-08-17PFIZER INC.$1,704Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-08-17PFIZER INC.$1,501Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-17PFIZER INC.$340Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-08-16PFIZER INC.$8,442Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-08-13PFIZER INC.$12,652Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-08-10PFIZER INC.$5,338Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-09PFIZER INC.$1,500Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-08-09PFIZER INC.$947Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-08-05PFIZER INC.$1,794Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2022
2022-08-04PFIZER INC.$10,790Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-04PFIZER INC.$6,113Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-04PFIZER INC.$4,194Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-04PFIZER INC.$1,704Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-08-04PFIZER INC.$1,363Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-08-03PFIZER INC.$34,000Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-08-03PFIZER INC.$33,129Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-08-03PFIZER INC.$22,672Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-08-02PFIZER INC.$2,340Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-02PFIZER INC.$1,906Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-08-02PFIZER INC.$1,589Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-07-28PFIZER INC.$18,878Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-07-28PFIZER INC.$8,371Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-07-28PFIZER INC.$1,877Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-07-27PFIZER INC.$3,000Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-07-27PFIZER INC.$1,906Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-07-27PFIZER INC.$1,500Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-07-27PFIZER INC.$1,020Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-07-27PFIZER INC.$650Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-07-27PFIZER INC.$110Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-07-22PFIZER INC.$19,972Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2022
2022-07-20PFIZER INC.$5,113Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-07-20PFIZER INC.$3,408Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-07-19PFIZER INC.$8,833Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-07-13PFIZER INC.$340Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-07-12PFIZER INC.$39,212Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-07-06PFIZER INC.$161,699Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-07-06PFIZER INC.$127,281Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-07-06PFIZER INC.$84,041Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-07-06PFIZER INC.$3,755Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-06-30PFIZER INC.$32,958Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-06-30PFIZER INC.$22,660Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-06-30PFIZER INC.$2,911Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-06-30PFIZER INC.$2,911Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-06-29PFIZER INC.$53,521Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-06-29PFIZER INC.$15,244Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-06-28PFIZER INC.$22,998Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-06-22PFIZER INC.$2,691Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2022
2022-06-21PFIZER INC.$1,595Research paymentCash or cash equivalentA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2022
2022-06-20PFIZER INC.$4,950Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-20PFIZER INC.$510Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-20PFIZER INC.$510Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-16PFIZER INC.$2,400Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-16PFIZER INC.$600Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-16PFIZER INC.$200Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-16PFIZER INC.$100Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-14PFIZER INC.$23,803Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-06-08PFIZER INC.$625Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-06-07PFIZER INC.$5,100Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-07PFIZER INC.$2,550Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-07PFIZER INC.$1,650Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-07PFIZER INC.$1,500Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-07PFIZER INC.$1,400Research paymentCash or cash equivalentA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2022
2022-06-07PFIZER INC.$1,100Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-07PFIZER INC.$1,050Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-07PFIZER INC.$450Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-06-03PFIZER INC.$2,691Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2022
2022-06-03PFIZER INC.$970Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-06-03PFIZER INC.$357Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-06-02PFIZER INC.$207,354Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-05-26PFIZER INC.$28,423Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-05-25PFIZER INC.$14,652Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-05-25PFIZER INC.$4,381Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-05-25PFIZER INC.$625Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-05-24PFIZER INC.$9,482Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-05-24PFIZER INC.$6,422Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2022
2022-05-21PFIZER INC.$2,401Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-05-21PFIZER INC.$1,328Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-05-20PFIZER INC.$46,560Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-05-20PFIZER INC.$8,245Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-05-20PFIZER INC.$2,800Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-05-20PFIZER INC.$625Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-05-13PFIZER INC.$17,236Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-05-06PFIZER INC.$5,525Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2022
2022-05-06PFIZER INC.$3,832Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-05-06PFIZER INC.$2,504Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-05-05PFIZER INC.$10,658Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-05-03PFIZER INC.$8,254Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-05-03PFIZER INC.$2,503Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-04-30PFIZER INC.$8,071Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-04-28PFIZER INC.$11,745Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-04-27PFIZER INC.$1,251Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-04-27PFIZER INC.$750Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-04-27PFIZER INC.$300Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-04-22PFIZER INC.$9,454Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-04-22PFIZER INC.$7,562Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-04-22PFIZER INC.$2,834Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2022
2022-04-20PFIZER INC.$21,262Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-04-20PFIZER INC.$3,523Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-04-19PFIZER INC.$29,060Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-04-19PFIZER INC.$7,603Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-04-19PFIZER INC.$1,877Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-04-16PFIZER INC.$18,044Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-04-13PFIZER INC.$21,853Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-04-08PFIZER INC.$4,771Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2022
2022-04-07PFIZER INC.$13,760Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-04-05PFIZER INC.$625Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-04-01PFIZER INC.$47,850Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-04-01PFIZER INC.$1,807Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-04-01PFIZER INC.$544Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-03-31PFIZER INC.$5,549Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-03-31PFIZER INC.$1,941Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-03-31PFIZER INC.$1,440Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-31PFIZER INC.$750Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-31PFIZER INC.$660Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-31PFIZER INC.$300Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-31PFIZER INC.$150Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-31PFIZER INC.$125Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-03-29PFIZER INC.$34,140Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-29PFIZER INC.$30,340Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-29PFIZER INC.$28,820Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-29PFIZER INC.$25,360Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-29PFIZER INC.$22,680Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-29PFIZER INC.$21,750Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-29PFIZER INC.$14,640Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-29PFIZER INC.$1,875Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-29PFIZER INC.$1,251Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-03-29PFIZER INC.$625Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-03-29PFIZER INC.$625Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-03-23PFIZER INC.$8,970Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-03-23PFIZER INC.$8,160Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-23PFIZER INC.$7,410Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-03-23PFIZER INC.$7,247Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2022
2022-03-23PFIZER INC.$4,125Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-23PFIZER INC.$1,650Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2022
2022-03-22PFIZER INC.$6,951Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-03-22PFIZER INC.$2,503Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022

The latest 200 records of 284.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Contra Costa CountyAntioch city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Antioch, CA, county Contra Costa County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Antioch, CA
County
Contra Costa County, CA
State
California
Population B01003116,4771,165,01239,287,377
Population, 2020 census P1115,2911,165,92739,538,223
Median age B0100238.440.537.9
Under 18 B0100122.8%22.0%22.0%
65 and over B0100114.3%17.1%15.7%
Households B1100137,381414,41713,548,091
Foreign born B0500224.6%26.6%27.0%
Median household income B19013$97,465$127,229$99,122
Median family income B19113$109,115$148,679$113,346
Per capita income B19301$41,008$62,927$49,513
Poverty rate B1700111.4%8.4%12.0%
Unemployment rate B230257.4%6.5%6.6%
Civilian labor force B2302560,709608,62020,068,466
Mean commute (minutes) B0801342.035.328.7
Bachelor's degree or higher B1500323.9%45.2%37.1%
Housing units B2500138,629429,26014,644,735
Owner-occupied B2500363.6%68.0%55.9%
Renters B2500336.4%32.0%44.1%
Median home value B25077$629,700$866,800$734,700
Median gross rent B25064$2,278$2,375$2,036
White, not Hispanic B0300223.4%38.1%33.8%
Black B0300218.2%7.9%5.2%
Hispanic or Latino B0300235.6%27.6%40.2%
Asian B0300213.9%18.6%15.3%
American Indian and Alaska Native B030020.5%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Antioch, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.